January 13, 2024
2 min watch
Save
VIDEO: Duker shares EyePoint pipeline progress
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye/Retina 2024, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses the phase 2 DAVIO 2 results for EYP-1901 for the treatment of wet AMD.
“The DAVIO 2 trial consisted of 160 patients randomly assigned to either 2 mg of EYP-1901 or 3 mg of EYP-1901 vs. an on-label aflibercept control,” Duker said. “The topline results showed that both doses of EYP-1901 were both essentially were equivalent for visual acuity to the on-label aflibercept; however, EYP-1901 can last between 6 months and up to 9 months with a single injection.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Duker reports being president and CEO of EyePoint Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.